Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) represent the current gold standard in pharmacological weight management. Both are injectable peptides, both produce unprecedented weight loss compared to older drugs, and both are now FDA-approved. But they are not the same — tirzepatide's dual mechanism produces meaningfully greater weight loss, though semaglutide has a longer safety track record.
Mechanism of Action
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 is naturally released after eating and signals to the brain to reduce appetite, slows gastric emptying, and stimulates insulin secretion. Semaglutide mimics this hormone with a 7-day half-life (vs natural GLP-1's 2-minute half-life), making once-weekly dosing possible.
Tirzepatide is a dual GIP/GLP-1 receptor co-agonist. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that acts synergistically with GLP-1. The dual action amplifies both appetite suppression and metabolic effects, which explains tirzepatide's superior weight loss outcomes.
The key difference: tirzepatide activates two distinct pathways simultaneously, while semaglutide activates one.
Clinical Trial Data: Weight Loss Outcomes
Semaglutide (STEP trials):
- Average weight loss: 14.9% body weight at 68 weeks (STEP 1, 1961 patients)
- Compared to placebo: 14.9% vs 2.4%
- 86.4% of patients lost ≥5% body weight
Tirzepatide (SURMOUNT trials):
- Average weight loss: 20.9% body weight at 72 weeks (SURMOUNT-1, 2539 patients) at 15mg dose
- 91% of patients lost ≥5% body weight
- At max dose (15mg): average 22.5% body weight loss in some cohorts
Head-to-head (SURPASS-6 trial, tirzepatide vs semaglutide in T2D):
- Tirzepatide 15mg: 13.1% HbA1c reduction, greater weight loss
- Semaglutide 1mg: 8.7% HbA1c reduction
Bottom line: Tirzepatide consistently outperforms semaglutide by approximately 5-7 percentage points of body weight.
Side Effects Comparison
Both share similar GI side effects as the primary adverse events. The GI side effects are dose-dependent and usually peak in the first 4-8 weeks.
Both peptides:
- Nausea (most common — 44% semaglutide vs 31-33% tirzepatide at lower doses)
- Vomiting, diarrhea, constipation
- Decreased appetite (intended effect)
Tirzepatide-specific concerns: Higher GIP activity may cause slightly different tolerability in some patients.
Serious but rare (both):
- Pancreatitis (black box warning)
- Gallbladder disease (increased risk with rapid weight loss)
- Thyroid C-cell tumors (rodent studies; unknown human risk — black box warning)
- Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2
Muscle loss: Both cause some lean mass loss alongside fat loss. Resistance training during treatment is strongly recommended.
Dosing and Administration
Semaglutide (Wegovy — weight management dosing):
- Week 1-4: 0.25mg/week SubQ
- Week 5-8: 0.5mg/week
- Week 9-12: 1mg/week
- Week 13-16: 1.7mg/week
- Week 17+: 2.4mg/week (maintenance dose)
Tirzepatide (Zepbound — weight management dosing):
- Week 1-4: 2.5mg/week SubQ
- Week 5-8: 5mg/week
- Week 9-12: 7.5mg/week (some stop here)
- Week 13-16: 10mg/week
- Week 17-20: 12.5mg/week
- Week 21+: 15mg/week (max dose)
Both use a slow dose escalation to minimize GI side effects.
Cost and Availability
Semaglutide:
- Brand (Wegovy): ~$1,350/month without insurance
- Generic/compounded: Available from compounding pharmacies during shortage period (FDA status varies)
Tirzepatide:
- Brand (Zepbound): ~$1,060-1,350/month without insurance
- Compounded: Similar availability to semaglutide
Insurance coverage: Both have GLP-1 coverage for type 2 diabetes (Ozempic, Mounjaro) but coverage for obesity (Wegovy, Zepbound) varies significantly by plan and state.
Research peptide market: Semaglutide and tirzepatide are available from research peptide suppliers, though quality verification is essential — always verify COA documentation.
Key Takeaways
If weight loss is the primary goal and tolerability is not a concern, tirzepatide's clinical data is superior. If you have been on semaglutide successfully and are comfortable with its side effect profile, there may be less reason to switch. Both are extraordinary advances over prior-generation obesity medications and represent a new era in metabolic pharmacology.